Pharma BD Deal Intelligence
A $3.4B deal that delivered exactly what it promised: Nurofen and Strepsils became durable Reckitt "powerbrands" still posting double-digit growth two decades later, though Clearasil proved non-core and Nurofen carried a real reputational scar from Australia's mislabeling prosecution.
Nurofen and Strepsils became durable Reckitt "powerbrands" still growing double digits two decades later; Clearasil proved non-core and was shopped for divestiture, and Nurofen carried a real reputational/legal scar from the Australian "Specific Pain" mislabeling case.
Full analysis, sources & comparables →Reckitt is paying 3.6 times sales and 20 times EBITDA versus 2.5-3 times sales and about 14 times EBITDA on comparable sector deals; analysts had not expected…
October 2005 BHI announcement framed as a strategic pivot into branded OTC pharma — explicitly the structural foundation for Reckitt's subsequent Adams…
Case No COMP/M.4007 Reckitt Benckiser / Boots Healthcare International, Regulation (EC) No 139/2004 merger procedure: Article 6(1)(b) non-opposition decision…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Reckitt Benckiser acquires Boots OTC business for £1.9B (~$3.4B). Adds Nurofen, Strepsils, Clearasil to consumer health portfolio.
Nurofen and Strepsils became durable Reckitt "powerbrands" still growing double digits two decades later; Clearasil proved non-core and was shopped for divestiture, and Nurofen carried a real reputational/legal scar from the Australian "Specific Pain" mislabeling case.
Assessment window: 15yr post-close.
This transaction is the announcement-stage record (Oct 2005) of the same Reckitt Benckiser purchase of Boots Healthcare International (BHI) that closed in early 2006. BHI's portfolio is consumer OTC self-care: Nurofen analgesics, Strepsils sore-throat lozenges, and Clearasil acne care, serving everyday self-medication across Europe, Asia and emerging markets.
On announcement, Reckitt outbid GlaxoSmithKline Consumer Healthcare and Bayer Consumer Care for BHI — both incumbents with deeper OTC scale via Panadol/Sensodyne and Aleve/Bayer Aspirin respectively, alongside J&J (Tylenol, Motrin IB) and Pfizer Consumer Healthcare (Advil). Per PharmaTimes, CEO Bart Becht framed BHI as the lever to take combined H&PC revenue above £1B (+90%, ~26% of the enlarged group) and guided to £75M cost synergies and £130M working-capital synergies by 2008. The Grocer noted Boots CEO Richard Baker's support for the deal, and equity markets responded positively (Reckitt +61p to £17.67 on announcement). Strategically the deal converted Reckitt from a hygiene/home-cleaning specialist into a credible OTC platform, anchored on Nurofen (a top European ibuprofen brand). It set up the company's subsequent OTC bolt-ons — Adams Respiratory (Mucinex, 2007) and SSL International (Durex, Scholl, 2010) — and is the structural starting point for what is now the Reckitt Health business unit. Sources: https://pharmatimes.com/news/reckitt_benckiser_buys_boots_otc_for_1-9bn_998907/ and https://www.thegrocer.co.uk/news/reckitt-benckiser-buys-boots-healthcare-international/104935.article
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Boots Healthcare International (this deal) | 2005 | $3.4B | 78 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. | 2012 | $1.4B | 67 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |